PepGen (PEPG) Preferred Stock Liabilities (2021 - 2022)
PepGen (PEPG) posted Preferred Stock Liabilities of $112.1 million for Q1 2022, up 1225.8% sequentially from $8.5 million in Q4 2021, and up 1359.41% YoY from $7.7 million in Q1 2021.
Powered by 
Analysis
PepGen (PEPG) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
PepGen has reported Preferred Stock Liabilities for 2 years, with the latest figure at $112.1 million in Q1 2022.
- Quarterly Preferred Stock Liabilities rose 1359.41% year-over-year to $112.1 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $112.1 million (up 1359.41% YoY) and the FY2021 annual result came in at $8.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $112.1 million in Q1 2022 per PEPG's latest filing, from $8.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $112.1 million in Q1 2022 and troughed at $7.7 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 165.18 Mn |
| Dec 31, 2021 | 226,000.00 |
| Sep 30, 2021 | 112.08 Mn |
| Jun 30, 2021 | 23.66 Mn |
| Mar 31, 2021 | 8.45 Mn |